CY1110808T1 - Συνδυαστικες βιβλιοθηκες μονομερων περιοχων - Google Patents

Συνδυαστικες βιβλιοθηκες μονομερων περιοχων

Info

Publication number
CY1110808T1
CY1110808T1 CY20101100871T CY101100871T CY1110808T1 CY 1110808 T1 CY1110808 T1 CY 1110808T1 CY 20101100871 T CY20101100871 T CY 20101100871T CY 101100871 T CY101100871 T CY 101100871T CY 1110808 T1 CY1110808 T1 CY 1110808T1
Authority
CY
Cyprus
Prior art keywords
polymers
methods
distinct
regions
immunoregions
Prior art date
Application number
CY20101100871T
Other languages
English (en)
Inventor
Joost A. Kolkman
Willem P.C. Stemmer
Original Assignee
Amgen Mountain View Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Mountain View Inc. filed Critical Amgen Mountain View Inc.
Publication of CY1110808T1 publication Critical patent/CY1110808T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/0068—Means for controlling the apparatus of the process
    • B01J2219/00702—Processes involving means for analysing and characterising the products
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polymerisation Methods In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Παρέχονται μέθοδοι ταυτοποίησης διακριτών μονομερών περιοχών και ανοσοπεριοχών με επιθυμητή ιδιότητα. Παρέχονται επίσης μέθοδοι για παραγωγή πολυμερών από δύο ή περισσότερες επιλεγμένες διακριτές μονομερείς περιοχές, μαζί με μεθόδους ταυτοποίησης πολυμερών που διαθέτουν επιθυμητή ιδιότητα. Παρέχονται επίσης συστήματα παρουσίασης που παρουσιάζουν τις διακριτές μονομερείς περιοχές και/ή ανοσοπεριοχές, επιλεγμένες μονομερείς περιοχές και/ή ανοσοπεριοχές, πολυμερή και/ή επιλεγμένα πολυμερή για να καταστεί δυνατή η επιλογή τους. Συνθέσεις, βιβλιοθήκες και κύτταρα που εκφράζουν ένα ή περισσότερα μέλη βιβλιοθήκης, μαζί με κιτ και ολοκληρωμένα συστήματα, περιλαμβάνονται επίσης στην παρούσα εφεύρεση.
CY20101100871T 2001-04-26 2010-09-28 Συνδυαστικες βιβλιοθηκες μονομερων περιοχων CY1110808T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28682301P 2001-04-26 2001-04-26
US33720901P 2001-11-19 2001-11-19
US33335901P 2001-11-26 2001-11-26
US37410702P 2002-04-18 2002-04-18
PCT/US2002/013257 WO2002088171A2 (en) 2001-04-26 2002-04-26 Combinatorial libraries of monomer domains

Publications (1)

Publication Number Publication Date
CY1110808T1 true CY1110808T1 (el) 2012-05-23

Family

ID=27501442

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100871T CY1110808T1 (el) 2001-04-26 2010-09-28 Συνδυαστικες βιβλιοθηκες μονομερων περιοχων

Country Status (11)

Country Link
US (2) US20030082630A1 (el)
EP (1) EP1390535B1 (el)
JP (1) JP4369662B2 (el)
AT (1) ATE472609T1 (el)
AU (1) AU2002256371B2 (el)
CA (1) CA2444854A1 (el)
CY (1) CY1110808T1 (el)
DE (1) DE60236861D1 (el)
DK (1) DK1390535T3 (el)
PT (1) PT1390535E (el)
WO (1) WO2002088171A2 (el)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) * 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) * 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7563600B2 (en) 2002-09-12 2009-07-21 Combimatrix Corporation Microarray synthesis and assembly of gene-length polynucleotides
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2432972A1 (en) * 2003-07-04 2005-01-04 Jeak L. Ding Sushi peptides, processes for making and uses thereof
CN101018559A (zh) * 2004-06-17 2007-08-15 安姆根山景公司 c－MET激酶结合蛋白
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060234299A1 (en) * 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
WO2006127040A2 (en) * 2004-11-16 2006-11-30 Avidia Research Institute Protein scaffolds and uses therof
EP1836223B1 (en) * 2005-01-03 2011-11-23 F. Hoffmann-La Roche AG Method for identifying a nucleic acid encoding a hemopexin-like structure which specifically binds a predetermined target molecule.
DE602006003695D1 (de) * 2005-01-05 2009-01-02 F Star Biotech Forsch & Entw Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
AU2011253661B2 (en) * 2005-04-26 2013-06-13 Boehringer Ingelheim Rcv Gmbh & Co Kg Production of recombinant proteins by autoproteolytic cleavage of a fusion protein
CA2605145A1 (en) 2005-04-26 2006-11-02 Sandoz Ag Affinity ligands
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
JP2007008926A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
US20060286047A1 (en) * 2005-06-21 2006-12-21 Lowe David J Methods for determining the sequence of a peptide motif having affinity for a substrate
AU2006268111A1 (en) * 2005-07-13 2007-01-18 Amgen Mountain View Inc. Il-6 binding proteins
US7820790B2 (en) 2005-07-13 2010-10-26 Amgen Mountain View Inc. IL-6 binding proteins
CN104844713B (zh) 2005-11-23 2021-05-14 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
EP2674440B1 (en) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
GB2433591A (en) * 2005-12-20 2007-06-27 Sharp Kk Method for functionalising a hydrophobic substrate
GB2433505A (en) * 2005-12-20 2007-06-27 Sharp Kk Capture agents for binding a ligand
GB2433506A (en) * 2005-12-20 2007-06-27 Sharp Kk A method of producing a multimeric capture agent
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
ATE473758T1 (de) * 2006-04-13 2010-07-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Her-2/neu multipeptidimpfstoff
WO2007136834A2 (en) * 2006-05-19 2007-11-29 Codon Devices, Inc. Combined extension and ligation for nucleic acid assembly
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP2423332A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
WO2008027558A2 (en) 2006-08-31 2008-03-06 Codon Devices, Inc. Iterative nucleic acid assembly using activation of vector-encoded traits
WO2008030611A2 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
PT2486941T (pt) 2006-10-02 2017-05-30 Squibb & Sons Llc Anticorpos humanos que ligam a cxcr4 e utilizações dos mesmos
CA2666507A1 (en) * 2006-10-16 2008-04-24 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona A Cting For And On Behalf Of Arizona State University Synthetic antibodies
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
JP5398538B2 (ja) 2006-12-01 2014-01-29 メダレックス・リミテッド・ライアビリティ・カンパニー Ｃｄ２２に結合するヒト抗体およびその使用
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
WO2008076368A2 (en) * 2006-12-13 2008-06-26 Codon Devices, Inc. Fragment-rearranged nucleic acids and uses thereof
BRPI0720476B1 (pt) 2006-12-18 2022-05-31 Acceleron Pharma Inc Uso de um polipeptídeo de actrii para tratar anemia em um paciente humano
BRPI0806861A2 (pt) 2007-02-01 2014-08-05 Acceleron Pharma Inc Antagonistas de ativina-actriia e usos para tratar ou prevenir câncer de mama
TWI525102B (zh) 2007-02-09 2016-03-11 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
WO2008103475A1 (en) * 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
EP2118138A1 (en) 2007-03-12 2009-11-18 Esbatech AG Sequence based engineering and optimization of single chain antibodies
CN101801407B (zh) 2007-06-05 2013-12-18 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
WO2009000098A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
CN102838673B (zh) 2007-06-25 2016-05-11 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
RU2010111135A (ru) 2007-08-24 2011-10-27 Онкотерапи Сайенс, Инк. (Jp) Связанные со злокачественными опухолями гены cdca5. epha7. stk31 и wdhd1
RU2010111116A (ru) 2007-08-24 2011-09-27 Онкотерапи Сайенс, Инк. (Jp) Pkib и naaladl2 в качестве генов-мишеней в терапии и диагностике рака предстательной железы
CA2697513A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
JP2011517314A (ja) 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Ｅｇｆｒに結合する操作されたタンパク質に基づく標的化された治療薬
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
KR101650165B1 (ko) 2008-06-25 2016-08-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역결합제의 용해도 최적화
US20100015144A1 (en) 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
DK2318028T3 (da) 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
EP3629022A1 (en) 2008-07-25 2020-04-01 Richard W. Wagner Protein screening methods
KR101127476B1 (ko) * 2008-08-11 2012-03-23 아주대학교산학협력단 크링글 도메인의 구조에 기반한 단백질 골격 라이브러리 및 그 용도
EP2323695B1 (en) 2008-08-19 2018-12-05 Nektar Therapeutics Complexes of small-interfering nucleic acids
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
CA2742986C (en) * 2008-11-07 2015-03-31 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
JP2012515544A (ja) 2009-01-21 2012-07-12 オックスフォード ビオトヘラペウトイクス エルティーディー． Ｐｔａ０８９タンパク質
CN102448494B (zh) 2009-02-13 2016-02-03 免疫医疗公司 具有胞内可裂解的键的免疫共轭物
KR101769160B1 (ko) 2009-03-05 2017-08-17 옥스포드 바이오테라퓨틱스 리미티드 Ｃａｄｍ１에 특이적인 완전 인간 항체
KR101805201B1 (ko) 2009-03-30 2017-12-05 악셀레론 파마 인코포레이티드 Ｂｍｐ-ａｌｋ3 길항제 및 골 성장을 촉진시키는 사용되는 이의 용도
CN106188295A (zh) 2009-04-20 2016-12-07 牛津生物疗法有限公司 特异于钙粘素‑17的抗体
US20120244147A1 (en) 2009-08-17 2012-09-27 Theuer Charles P Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CA2773494A1 (en) 2009-09-09 2011-03-17 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
EP2496605A1 (en) 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2011056872A2 (en) 2009-11-03 2011-05-12 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
JP2013509869A (ja) 2009-11-05 2013-03-21 ノバルティス アーゲー 線維症の進行の予測用バイオマーカー
US9216414B2 (en) 2009-11-25 2015-12-22 Gen9, Inc. Microfluidic devices and methods for gene synthesis
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
WO2011085075A2 (en) 2010-01-07 2011-07-14 Gen9, Inc. Assembly of high fidelity polynucleotides
CA2789125A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
CN103118692A (zh) 2010-04-26 2013-05-22 Atyr医药公司 与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6294074B2 (ja) 2010-04-27 2018-03-14 エータイアー ファーマ， インコーポレイテッド イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
CN103118693B (zh) 2010-04-29 2017-05-03 Atyr 医药公司 与缬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
EP2566496B1 (en) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
WO2011140267A2 (en) 2010-05-04 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CA3090304A1 (en) 2010-05-13 2011-11-17 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
CN103200953B (zh) 2010-05-14 2017-02-15 Atyr 医药公司 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
MX2013000301A (es) 2010-07-09 2013-05-09 Biogen Idec Hemophilia Inc Factores quimericos de coagulacion.
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN103502448B (zh) 2010-11-12 2017-03-29 Gen9股份有限公司 核酸合成的方法和设备
US10457935B2 (en) 2010-11-12 2019-10-29 Gen9, Inc. Protein arrays and methods of using and making the same
CN107375293A (zh) 2011-03-11 2017-11-24 细胞基因公司 利用3‑(5‑氨基‑2‑甲基‑4‑氧‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮治疗癌症的方法
RS56770B1 (sr) 2011-03-11 2018-04-30 Celgene Corp Čvrste forme 3-(5-amino-2-metil-4-okso-4h-hinazolin-3-il)-piperidin-2,6-diona i njihove farmaceutske smeše i upotrebe
EP2726508B1 (en) 2011-06-28 2017-08-09 Oxford BioTherapeutics Ltd Antibodies to adp-ribosyl cyclase 2
RS55716B1 (sr) 2011-06-28 2017-07-31 Oxford Biotherapeutics Ltd Terapeutski i dijagnostički cilj
LT2944693T (lt) 2011-08-26 2019-08-26 Gen9, Inc. Kompozicijos ir būdai, skirti nukleorūgščių didelio tikslumo sąrankai
CA2852709A1 (en) 2011-10-28 2013-05-02 Patrys Limited Pat-lm1 epitopes and methods for using same
US20130156766A1 (en) 2011-11-15 2013-06-20 Allergan, Inc. Treatment of dry age related macular degeneration
HUE039033T2 (hu) 2012-01-10 2018-12-28 Biogen Ma Inc Terápiás molekulák transzportjának fokozása a vér-agy gáton keresztül
WO2013123432A2 (en) 2012-02-16 2013-08-22 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
US9150853B2 (en) 2012-03-21 2015-10-06 Gen9, Inc. Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
LT2841601T (lt) 2012-04-24 2019-07-10 Gen9, Inc. Nukleorūgščių rūšiavimo būdai ir multipleksinis preparatyvinis in vitro klonavimas
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
EP3483311A1 (en) 2012-06-25 2019-05-15 Gen9, Inc. Methods for nucleic acid assembly and high throughput sequencing
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
IL288506B2 (en) 2012-08-09 2023-09-01 Celgene Corp Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione
SI2882737T1 (sl) 2012-08-09 2019-05-31 Celgene Corporation Trdna oblika (S)-3-(4-((4-morfolinometil)benzil)oksi-1-oksoizoindolin-2-il) piperidin-2,6-dion hidroklorida
RS60416B1 (sr) 2012-08-09 2020-07-31 Celgene Corp Lečenje imunoloških i zapaljenskih bolesti
WO2014023315A1 (en) 2012-08-10 2014-02-13 Aarhus Universitet Multimerization through beta-strand swapping in ccp domains
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
JP6581505B2 (ja) 2012-10-03 2019-09-25 ザイムワークス，インコーポレイテッド 重鎖および軽鎖ポリペプチドの対を定量化する方法
ES2753811T3 (es) 2012-10-24 2020-04-14 Celgene Corp Biomarcador para uso en el tratamiento de anemia
EP3964224A1 (en) 2012-11-02 2022-03-09 Celgene Corporation Activin-actrii antagonists and uses for use in treating renal disease
CA2886987C (en) 2012-11-08 2022-07-12 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
PL2900277T3 (pl) 2012-12-13 2022-05-16 Immunomedics, Inc. Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2961412A4 (en) 2013-02-26 2016-11-09 Triact Therapeutics Inc CANCER THERAPY
WO2014133855A1 (en) 2013-02-28 2014-09-04 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
EP2774930A1 (en) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocene compounds and labeled molecules comprising the same for in vivo imaging.
US9157910B2 (en) 2013-03-15 2015-10-13 Abbott Laboratories Assay with increased dynamic range
CN105263514B (zh) 2013-03-15 2019-04-26 本质生命科学有限公司 抗铁调素抗体及其用途
US9005901B2 (en) 2013-03-15 2015-04-14 Abbott Laboratories Assay with internal calibration
MX371455B (es) 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
DK3074038T3 (en) 2013-11-28 2019-03-11 Csl Ltd METHOD OF TREATING DIABETIC NEPHROPATHY
JP6553618B2 (ja) 2013-12-18 2019-07-31 シーエスエル リミティド 創傷を治療する方法
JP6591437B2 (ja) 2014-03-20 2019-10-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン
US10398765B2 (en) 2014-07-03 2019-09-03 Yale University Dickkopf2 (Dkk2) inhibition suppresses tumor formation
ES2750689T3 (es) 2014-08-15 2020-03-26 Adynxx Inc Señuelos oligonucleotídicos para el tratamiento del dolor
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AU2015324924B2 (en) 2014-10-01 2021-07-01 Medimmune, Llc Method of conjugating a polypeptide
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
NZ731090A (en) 2014-11-07 2024-03-22 F Hoffmann La Roche Ltd Improved il-6 antibodies
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
ES2946160T3 (es) 2014-12-03 2023-07-13 Celgene Corp Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
EP4190805A3 (en) 2015-05-20 2023-08-16 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
CN107735104B (zh) 2015-06-25 2022-05-03 免疫医疗公司 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
CA3003252C (en) 2015-10-28 2024-06-25 Yale University Humanized anti-dkk2 antibody and uses thereof
CA3006758A1 (en) 2015-12-02 2017-06-08 Celgene Corporation Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
AU2017331739A1 (en) 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof
US20180258064A1 (en) 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
CN111247165B (zh) 2017-10-18 2023-11-10 Csl有限公司 人血清白蛋白变体及其应用
AU2018377856A1 (en) 2017-11-29 2020-05-21 Csl Limited Method of treating or preventing ischemia-reperfusion injury
WO2020176553A1 (en) * 2019-02-25 2020-09-03 Sense Therapeutics Inc. Intracellular mutation targeting therapy
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
AU2020235455A1 (en) 2019-03-08 2021-10-28 Oxford Genetics Limited Method of selecting for antibodies
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
US11725048B2 (en) 2019-12-20 2023-08-15 Hudson Institute of Medical Research CXCL10 binding proteins and compositions thereof
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
WO2024088921A1 (en) 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE64618T1 (de) * 1982-03-15 1991-07-15 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5473039A (en) * 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6329507B1 (en) * 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
WO1996013583A2 (en) * 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
CA2297070A1 (en) * 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
US6030771A (en) * 1997-08-25 2000-02-29 Centers For Disease Control And Prevention Mosaic protein and restriction endonuclease assisted ligation method for making the same
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CA2361292C (en) * 1999-03-16 2012-05-29 Edward A. Berger A novel chimeric protein for prevention and treatment of hiv infection
AUPQ339899A0 (en) * 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US20040171544A1 (en) * 2001-04-24 2004-09-02 Barker Nicholas P. Trefoil domain-containing polypeptides and uses thereof

Also Published As

Publication number Publication date
US20030082630A1 (en) 2003-05-01
AU2002256371B2 (en) 2008-01-10
CA2444854A1 (en) 2002-11-07
DK1390535T3 (da) 2010-12-06
JP2005519579A (ja) 2005-07-07
PT1390535E (pt) 2010-10-04
WO2002088171A2 (en) 2002-11-07
DE60236861D1 (de) 2010-08-12
ATE472609T1 (de) 2010-07-15
WO2002088171A3 (en) 2003-05-08
EP1390535A4 (en) 2005-01-05
JP4369662B2 (ja) 2009-11-25
EP1390535B1 (en) 2010-06-30
EP1390535A2 (en) 2004-02-25
US20050221384A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
CY1110808T1 (el) Συνδυαστικες βιβλιοθηκες μονομερων περιοχων
WO2004044011A3 (en) Combinatorial libraries of monomer domains
WO2005040229A3 (en) Ldl receptor class a and egf domain monomers and multimers
ES2505144T3 (es) Agentes de unión selectivos antagonistas de proteína de unión de osteoprotegerina
CY1105191T1 (el) Συνδετες διττης εξειδικευσης με αυξημενη ημιζωη ορου
CY1111649T1 (el) Αντισωμα εναντι της γλυπικανης 3
DK1252339T3 (da) Syntese af rumligt adresserbare molekylære opstillinger
BRPI0606287A2 (pt) processo para a produção de silicones monofuncionais monodispersos e dispersos limitados
DE60322715D1 (de) Vermischte dendrimere
CY1106032T1 (el) Υποκατασταθεισες πυραζολες
ATE480643T1 (de) Homogener nachweis von analyten
BR0309297A (pt) Artigo retrorreflexivo , e, método de preparar o mesmo
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
CY1105758T1 (el) Τροποποιημενη απιμιναση αργινινης
DK1470175T3 (da) Oligomere kædeforlængere til behandling, efterbehandling og recirkulering af kondensationspolymerer, syntese, sammensætninger og anvendelser
ES2125458T3 (es) Copolimeros de etileno que tienen una distribucion de la composicion estrecha, su produccion y uso.
CY1105694T1 (el) Τμηματικος υπολογιστης
BR0108603A (pt) Composições polìmeras com aperfeiçoada constância de propriedades
CY1105675T1 (el) Πρωτεϊνη ροσδενουσα αγγειοστατινη
DE50101208D1 (de) Weisse, hochglänzende, polyesterfolie enthaltend cycloolefincopolymer (coc), verfahren zu ihrer herstellung und ihre verwendung
ATE414795T1 (de) Antikörperbibliotheken
HK1084480A1 (en) Slide rule for misic
BR0211290A (pt) Compostos de catalisador de metaloceno de baixa incorporação de comonÈmero
AR000056A1 (es) Proceso para la preparación de polimeros de olefina estabilizados y poliolefinas estabilizadas, particularmente polietileno y polipropileno de alto peso molecular preparada segun dicho proceso.
ATE371749T1 (de) Matrix-screening-verfahren